COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01PQK
|
|||
Drug Name |
Ruxolitinib + simvastatin
|
|||
Synonyms |
Jakafi + MK 733
|
|||
Drug Type |
Combination drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL
|
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04348695) Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.